hbai20
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02540538)
Timeline
Indications
Studied for
Mechanism of action
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hbai20
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03415672 | Phase 2 | Oct 11, 2017 | CyTuVax, Maastricht University, University of Antwerp, Ziekenhuis Oost-Limburg |
| NCT02540538 | Phase 1 | Sep 1, 2015 | CyTuVax, Maastricht University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CyTuVax | For profit | 2 | 0 | 2 | 2015 |
| Maastricht University | Academic/Hospital | 2 | 2 | 2 | 2015 |
| University of Antwerp | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Ziekenhuis Oost-Limburg | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1